Varithena Versus Endothermal Ablation of the Great Saphenous Vein (VERITAS)

Exclusion Criteria

• •Allergy to polidocanol, xylocaine, or epinephrine
• •Deep vein thrombosis or pulmonary embolism within 3 months prior to randomization or hypercoagulable disorder
• •Post thrombotic deep vein disease above the calf veins
• •Pregnancy or lactating (within 30 days of randomization)
• •Symptomatic peripheral arterial disease or ankle-brachial pressure index (ABPI) \< 0.8
• •Previous treatment to targeted incompetent GSV or previous superficial thrombophlebitis in targeted GSV
• •Previous venous intervention in affected limb in past 3 months
• •Local aneurysmal GSV segments
• •Inability to walk unaided
• •Inability to wear post-procedure compression bandaging and stockings
• •Patients with clinically significant reflux of the small saphenous vein (SSV) or anterior accessory saphenous vein (AASV)
• •In the clinical judgement of the investigator, patient who will require ipsilateral deep venous intervention within 3 months following randomized treatment
• •In the clinical judgement of the investigator, patient who will require contralateral venous intervention (superficial or deep) within 3 months following randomized treatment
• •Patient on therapeutic anticoagulants
• •Active malignancy
• •Life expectancy \< 2 years
• •Documented COVID-19 infection currently or within 2 months prior to randomization
• •Enrollment in another clinical trial that could confound the endpoint within 3 months prior to screening or within 3 months following enrollment